240 related articles for article (PubMed ID: 37019248)
1. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.
Bell AS; Wagner J; Rosoff DB; Lohoff FW
Neurosci Biobehav Rev; 2023 Jun; 149():105155. PubMed ID: 37019248
[TBL] [Abstract][Full Text] [Related]
2. Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence.
Zhu XB; Xu YY; Li LC; Sun JB; Wang YZ; Chen J; Wang C; Zhang S; Jin LY
Drug Dev Res; 2024 Feb; 85(1):e22131. PubMed ID: 37943623
[TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders.
O'Connell EM; Lohoff FW
Front Neurosci; 2020; 14():609. PubMed ID: 32595449
[TBL] [Abstract][Full Text] [Related]
4. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
6. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
Dijk W; Le May C; Cariou B
Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
[TBL] [Abstract][Full Text] [Related]
7. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
8. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
Lu X
Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
Guo S; Xia XD; Gu HM; Zhang DW
Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
[TBL] [Abstract][Full Text] [Related]
10. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
11. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.
Bao X; Liang Y; Chang H; Cai T; Feng B; Gordon K; Zhu Y; Shi H; He Y; Xie L
Signal Transduct Target Ther; 2024 Jan; 9(1):13. PubMed ID: 38185721
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
14. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
15. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
[TBL] [Abstract][Full Text] [Related]
16. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
[No Abstract] [Full Text] [Related]
17. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
Pedro-Botet J; Badimón L
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
[TBL] [Abstract][Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
[TBL] [Abstract][Full Text] [Related]
19. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
Grewal T; Buechler C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
